Yang Xiao, Yu Hao, Chen Haonan, Liu Peikun, Tao Yiran, Bai Rongjie, Li Pengchao, Shao Pengfei, Li Jie, Cao Qiang, Lu Qiang
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
World J Urol. 2025 Jun 18;43(1):376. doi: 10.1007/s00345-025-05745-8.
Lateral positioning remains standard for retroperitoneal robotic-assisted partial nephrectomy (rRAPN). Emerging single-port systems have expanded supine positioning applications in rRAPN. This study evaluates the feasibility and safety of novel prone retroperitoneal RAPN (prRAPN).
From August 2023 to December 2024, 108 patients with renal tumors in various anatomical locations prospectively underwent prRAPN. Demographic and perioperative parameters were analyzed.
This prospective cohort (n = 108) demonstrated median age 59 years, BMI 24.6 kg/m², R.E.N.A.L. score 7, and PADUA score 9. 10 patients had stage ≥ 3 chronic kidney disease, 75 had an age-adjusted charlson comorbidity index ≥ 2 and 23 had an American Society of Anesthesiologists score ≥ 3. All 86 patients with renal malignancies achieved negative surgical margins. Operative outcomes demonstrated median hilar access time 5.3 min, warm ischemia time 20.3 min, operation time 47.3 min, and estimated blood loss 50 mL. Postoperative 90-day ΔeGFR decreased by 7.2 mL/(min·1.73m). Learning curve inflection points occurred at 52 cases for operation time. No conversions to open surgery or radical nephrectomy occurred, with one blood transfusion required. Nine minor and one major complications were recorded postoperatively. Limitations include small-sample size, short follow-up, and no controls.
Preliminary results demonstrated prRAPN is feasible and safe, which could expedite access to surgical area and improve exposure of posterior tumor. Larger-scale and multi-center studies are needed for confirmation.
侧卧位仍然是腹膜后机器人辅助部分肾切除术(rRAPN)的标准体位。新兴的单孔系统扩大了仰卧位在rRAPN中的应用。本研究评估新型俯卧位腹膜后RAPN(prRAPN)的可行性和安全性。
2023年8月至2024年12月,108例不同解剖部位肾肿瘤患者前瞻性地接受了prRAPN。分析了人口统计学和围手术期参数。
该前瞻性队列(n = 108)的中位年龄为59岁,体重指数为24.6kg/m²,R.E.N.A.L.评分7分,PADUA评分9分。10例患者患有≥3期慢性肾脏病,75例年龄调整后的查尔森合并症指数≥2,23例美国麻醉医师协会评分≥3。所有86例肾恶性肿瘤患者均实现了手术切缘阴性。手术结果显示,肾门入路中位时间为5.3分钟,热缺血时间为20.3分钟,手术时间为47.3分钟,估计失血量为50毫升。术后90天的估算肾小球滤过率(ΔeGFR)下降了7.2毫升/(分钟·1.73平方米)。手术时间的学习曲线拐点出现在52例时。未发生转为开放手术或根治性肾切除术的情况,仅需1次输血。术后记录了9例轻微并发症和1例严重并发症。局限性包括样本量小、随访时间短且无对照组。
初步结果表明prRAPN是可行且安全的,可加快进入手术区域并改善后位肿瘤的暴露。需要更大规模的多中心研究进行证实。